N-formyl-sulfanilyl chloride | 34894-11-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-formyl-sulfanilyl chloride
• 英文别名: N-Formyl-sulfanilylchlorid；4-Formylamino-phenylsulfonsaeurechlorid；4-Formamidobenzene-1-sulfonyl chloride；4-formamidobenzenesulfonyl chloride
• CAS: 34894-11-6
• 化学式: C₇H₆ClNO₃S
• mdl: MFCD11139145
• 分子量: 219.649
• InChiKey: XLVLOSDNUCWQEC-UHFFFAOYSA-N

物化性质

• 熔点：
  154-155 °C
• 沸点：
  411.0±28.0 °C(Predicted)
• 密度：
  1.537±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-formyl-sulfanilyl chloride 在 ammonium hydroxide 作用下， 生成 磺胺
  参考文献：
  名称：

  磺胺新工艺

  摘要：

  DOI：

  10.1021/ie50410a023
• 作为产物：
  描述：

  N-苯基甲酰胺 在 chlorosulphuric acid 作用下， 生成 N-formyl-sulfanilyl chloride
  参考文献：
  名称：

  Bras; Al'bizkaja; Schkral', Zhurnal Prikladnoi Khimii, 1944, vol. 17, p. 502,504

  摘要：

  DOI：

文献信息

• [EN] POLYETHYLENE GLYCOL CONJUGATES OF HETEROCYCLOALKYL CARBOXAMIDO PROPANOIC ACIDS<br/>[FR] CONJUGUES A BASE DE POLYETHYLENE GLYCOL D'ACIDES HETEROCYCLOALKYL CARBOXAMIDO PROPANOIQUES
  申请人：ELAN PHARM INC

  公开号：WO2005070921A1

  公开（公告）日：2005-08-04

  Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer’s disease, atherosclerosis, AIDS, dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  公开的是结合VLA-4的偶联物。其中一些偶联物还抑制白细胞粘附，尤其是VLA-4介导的白细胞粘附。这类偶联物可用于治疗哺乳动物患者，如人类的炎症性疾病，例如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病、痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些偶联物还可用于治疗炎症性脑病，如多发性硬化症。
• Multimeric VLA-4 antagonists comprising polymer moieties
  申请人：Konradi W. Andrei

  公开号：US20060013799A1

  公开（公告）日：2006-01-19

  Disclosed are conjugates which bind VLA-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  公开的是结合VLA-4的偶联物。其中一些偶联物还能抑制白细胞粘附，特别是VLA-4介导的白细胞粘附。这类偶联物可用于治疗哺乳动物患者，如人类的炎症性疾病，例如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些偶联物还可用于治疗炎症性脑病，如多发性硬化症。
• Inhibitors of histone deacetylase
  申请人：Anandan K. Sampath

  公开号：US20050250784A1

  公开（公告）日：2005-11-10

  Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC.

  揭示了抑制组蛋白去乙酰化酶（HDAC）酶活性的化合物。还揭示了包含这些化合物的药物组合物，以及治疗由HDAC至少部分介导的疾病的方法，特别是增殖性疾病。
• [EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ELAN PHARM INC

  公开号：WO2004098589A1

  公开（公告）日：2004-11-18

  Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  公开的是化合物I和II的结构式，它们是激肽酶B1受体拮抗剂，适用于治疗哺乳动物中由激肽酶B1受体介导的疾病，或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计还将表现出延长作用的特性。
• [EN] SULFONYLBENZODIAZEPINONE ACETAMIDES AS BRADYKININ ANTAGONISTS<br/>[FR] SULFONYLBENZODIAZEPINONE ACETAMIDES UTILISES COMME ANTAGONISTES DE LA BRADYKININE
  申请人：ELAN PHARM INC

  公开号：WO2004033436A1

  公开（公告）日：2004-04-22

  Disclosed are compounds, of formula (I) which are bradykinin antagonists and are useful to treat diseases or relieve adverse symptoms associated with disease conditions in mammals mediated by bradykinin. Certain of the compounds exhibit increased potency and are expected to also exhibit an increased duration of action.

  揭示了一些化合物，其化学式为（I），它们是激肽酶抑制剂，并可用于治疗或缓解哺乳动物中由激肽酶介导的疾病或与疾病状况相关的不良症状。其中一些化合物表现出增强的效力，并预计也将表现出延长的作用时间。